SCHEMBL4024959

SCHEMBL4024959

CC(C)(C)OC(=O)C1OC1c1ccc(OCc2ccccc2)cc1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAOB P27338 1/20 0.48
TSHR P16473 1/20 0.47
NR4A1 P22736 1/20 0.47
NR4A2 P43354 1/20 0.47
NR4A3 Q92570 1/20 0.47
KDM4E B2RXH2 1/20 0.45
MEN1 O00255 1/20 0.45
MAPT P10636 1/20 0.45
KMT2A Q03164 1/20 0.45
LTA4H P09960 1/20 0.45
PARP10 Q53GL7 1/20 0.45
PTGS1 P23219 2/20 0.44
PTGS2 P35354 2/20 0.44
PPARG P37231 1/20 0.44
LMNA P02545 1/20 0.44
CYP1A2 P05177 1/20 0.44
SLC6A2 P23975 1/20 0.44
CYP2C19 P33261 1/20 0.44
SLC6A3 Q01959 1/20 0.44
HIF1A Q16665 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9692676 0.86 NPC1 (0.53) MAOBTSHRNR4A1NR4A2NR4A3
SCHEMBL7926767 0.83 NR4A1 (0.55) MAOBNR4A1NR4A2NR4A3PARP10
SCHEMBL9488854 0.82 TSHR (0.61) MAOBTSHRMEN1KMT2ACYP1A2
SCHEMBL7772636 0.82 TSHR (0.61) MAOBTSHRMEN1KMT2ACYP1A2
SCHEMBL16303826 0.82 TSHR (0.61) MAOBTSHRMEN1KMT2ACYP1A2
SCHEMBL7770452 0.82 TSHR (0.61) MAOBTSHRMEN1KMT2ACYP1A2
SCHEMBL27902768 0.81 KDM4E (0.50) MAOBNR4A1NR4A2NR4A3KDM4E
SCHEMBL14967144 0.81 TSHR (0.45) TSHRKDM4EMAPTPTGS2LMNA
SCHEMBL7760857 0.81 TSHR (0.45) TSHRKDM4EMAPTPTGS2LMNA
SCHEMBL29926003 0.78 TSHR (0.45) TSHRKDM4ELMNAFFAR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090216024-A1 Processes for making pioglitazone and compounds of the processes ZHU JIE 2009-08-27 US disclosed
US-7541470-B2 Processes for making pioglitazone and compounds of the processes SYNTHON IP INC. (US) 2009-06-02 US disclosed
US-20070167629-A1 Processes for making pioglitazone and compounds of the processes SYNTHON IP INC. 2007-07-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090216024-A1 Processes for making pioglitazone and compounds of the processes PDK4, PDK2, DPP4 MAOB 2235/4885TSHR 1096/4885NR4A1 1522/4885
US-20070167629-A1 Processes for making pioglitazone and compounds of the processes PDK4, PDK2, DPP4 MAOB 2235/4885TSHR 1096/4885NR4A1 1522/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.